ALOX12

Across TCGA pan-cancer cohorts, ALOX12 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ALOX12’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ALOX12 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ALOX12 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where ALOX12 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALOX12 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−0.815	<.001	8	view →
LUAD	All	All	−0.682	<.001	4	view →
LSCC	All	All	−0.276	.004	4	view →
OV	All	All	−3.250	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ALOX12–HNSC

Open the HNSC breakdown →